Red Light Therapy for Neuro-Rehabilitation

There is emerging evidence supporting PBM in neurological rehabilitation, particularly in relation to energy metabolism, fatigue reduction, and support of cognitive and motor function. It is best understood as a supportive adjunct rather than a disease-modifying treatment.

Clinical evidence is still emerging, but reviews and meta-analyses have reported signals of improvement in cognitive outcomes (including global cognition, working memory and executive function) in some cognitive impairment populations, with substantial variation between studies and protocols. The literature also includes Alzheimer’s-focused reviews and ongoing clinical trials, which reflects growing interest but also that the field is still maturing. (Springer Link)

How we frame this clinically: PBM is considered a supportive adjunct to help optimise capacity and daily function. It is not presented as a treatment that stops progression or replaces medical care. (PMC)

There are reviews describing promising preclinical findings and a small but growing clinical literature suggesting PBM may support motor and non-motor symptoms in Parkinson’s disease, with feasibility and safety explored in early trials. However, most studies to date are small and further adequately powered randomised trials are still needed. (PMC)

How we frame this clinically: our OT lens is function-first, focusing on gait initiation, dual-task tolerance, fatigue and participation, rather than claiming disease modification. (PMC)

Systematic reviews in MS describe PBM as a promising non-pharmacological approach with evidence spanning preclinical mechanisms and some clinical observations across symptoms and function, but they also highlight major limitations such as protocol variability and the need for stronger human trials and standardisation. (Frontiers)

How we frame this clinically: PBM may be considered where fatigue, pain, or load tolerance is limiting function, and always as part of a wider rehabilitation plan rather than a stand-alone intervention. (PMC)

There are systematic reviews and narrative syntheses describing transcranial PBM as a potential adjunct for TBI recovery, including cognitive outcomes in clinical trials. Evidence suggests possible benefits in some domains, but studies vary widely in devices, parameters, and outcome measures, which limits certainty. (Frontiers)

A more recent randomised placebo-controlled study in mild TBI also examined cognitive effects, again highlighting promise alongside the reality that sample sizes remain small. (PubMed)

How we frame this clinically: PBM is positioned as a tool to support capacity (fatigue, focus, tolerance), then immediately linked to functional therapy tasks. (Frontiers)

“Concussion” research often sits within the broader mild TBI literature, including athlete cohorts. Reviews and clinical reports describe potential improvements across domains like sleep, reaction time and symptom burden in some populations, but much of the literature still includes small trials, cohorts, and case-based evidence rather than large definitive RCTs. (MDPI)

How we frame this clinically: PBM may be considered when symptoms are lingering and capacity is limiting return to work, study, or training, and is integrated with a graded return-to-activity plan. (MDPI)

Evidence for PBM in PTSD is early. A 2025 study in a firefighter cohort reported pre/post improvements in mood and post-traumatic stress symptoms following transcranial PBM, but this does not yet constitute definitive proof or establish PBM as a standard PTSD treatment. (Liebert Publications)
There are also broader reviews looking at near-infrared stimulation across psychiatric disorders, again highlighting emerging interest alongside limited high-quality PTSD-specific trials. (MDPI)

How we frame this clinically: we do not position PBM as a replacement for psychological therapy. Where appropriate, it may be used to support sleep, regulation, and cognitive load tolerance as part of a broader care plan. (Liebert Publications)

PBM does not stop disease progression or restore lost neurons. Its role is to support capacity and participation. For some people, this may translate into clearer thinking, better tolerance to activity, and improved quality of life.

People commonly report less mental fatigue, improved clarity or focus, a greater sense of calm, and better tolerance to therapy or daily tasks.

Changes are often subtle but meaningful rather than dramatic.

Home devices use fixed, non-individualised dosing. In neurological conditions, incorrect dosing may lead to no benefit or increased fatigue. Clinical supervision allows dosing to be adjusted, monitored, and integrated with therapy goals.

The PBM evidence base is expanding, but quality varies by condition. Across neurological applications, research is often limited by small sample sizes, heterogenous protocols (wavelengths, irradiance, treatment sites, and session schedules), and diverse outcome measures. This is why we emphasise clinical suitability assessment, individualised dosing, and functional outcome tracking, and we avoid claims of cure or guaranteed results. (PMC)